$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000155905317000025 Filed on August 09, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$219.0K	$26.81M	$333.0K
YoY Change	-23.43%	7951.65%	19.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.44M	$10.91M	$8.130M
YoY Change	-22.92%	34.19%	47.28%
% of Gross Profit
Research & Development	$41.32M	$34.03M	$32.36M
YoY Change	53.94%	5.17%	152.98%
% of Gross Profit
Depreciation & Amortization	$800.0K	$800.0K	$400.0K
YoY Change	0.0%	100.0%	100.0%
% of Gross Profit
Operating Expenses	$53.75M	$44.94M	$40.49M
YoY Change	25.08%	10.99%	121.12%
Operating Profit	-$53.53M	-$18.13M	-$40.16M
YoY Change	25.41%	-54.85%	122.68%
Interest Expense	$120.0K	$20.00K	-$10.00K
YoY Change	-14.29%	-300.0%	-125.0%
% of Operating Profit
Other Income/Expense, Net	-$565.0K	-$856.0K	-$96.00K
YoY Change	334.62%	791.67%	104.26%
Pretax Income	-$54.10M	-$18.99M	-$40.26M
YoY Change	26.35%	-52.83%	122.63%
Income Tax	-$1.705M	-$1.287M	$189.0K
% Of Pretax Income
Net Earnings	-$52.39M	-$17.70M	-$40.45M
YoY Change	21.17%	-56.23%	121.29%
Net Earnings / Revenue	-23924.2%	-66.02%	-12145.65%
Basic Earnings Per Share	-$1.37	-$0.46	-$1.18
Diluted Earnings Per Share	-$1.37	-$0.46	-$1.18
COMMON SHARES
Basic Shares Outstanding	38.28M shares	38.02M shares	34.35M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$456.1M	$471.7M	$442.9M
YoY Change	11.63%	6.5%	10.06%
Cash & Equivalents	$456.1M	$471.7M	$442.9M
Short-Term Investments
Other Short-Term Assets	$12.80M	$9.800M	$7.300M
YoY Change	91.04%	34.25%	151.72%
Inventory
Prepaid Expenses
Receivables	$220.0K	$30.24M	$364.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$469.1M	$511.7M	$450.6M
YoY Change	12.85%	13.56%	10.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$55.38M	$55.84M	$41.85M
YoY Change	7.05%	33.43%	1386.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.784M	$1.625M	$2.363M
YoY Change	28.77%	-31.23%	12.52%
Total Long-Term Assets	$68.62M	$67.28M	$51.96M
YoY Change	7.31%	29.47%	946.82%
TOTAL ASSETS
Total Short-Term Assets	$469.1M	$511.7M	$450.6M
Total Long-Term Assets	$68.62M	$67.28M	$51.96M
Total Assets	$537.7M	$579.0M	$502.6M
YoY Change	12.11%	15.21%	22.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.06M	$12.55M	$11.59M
YoY Change	4.95%	8.22%	304.61%
Accrued Expenses	$26.00M	$25.00M	$19.70M
YoY Change	15.04%	26.9%	116.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$400.0K
YoY Change
Total Short-Term Liabilities	$39.26M	$39.60M	$33.46M
YoY Change	6.37%	18.36%	148.63%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$52.20M	$52.40M	$126.0K
YoY Change		41487.3%	0.0%
Total Long-Term Liabilities	$52.17M	$52.43M	$38.24M
YoY Change	25.48%	37.09%	1437.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.26M	$39.60M	$33.46M
Total Long-Term Liabilities	$52.17M	$52.43M	$38.24M
Total Liabilities	$91.43M	$92.02M	$71.70M
YoY Change	16.49%	28.35%	349.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$394.6M	-$342.2M	-$197.1M
YoY Change	64.2%	73.64%	140.42%
Common Stock	$384.0K	$382.0K	$343.0K
YoY Change	11.63%	11.37%	9.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$446.3M	$487.0M	$430.9M
YoY Change
Total Liabilities & Shareholders Equity	$537.7M	$579.0M	$502.6M
YoY Change	12.11%	15.21%	22.23%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$52.39M	-$17.70M	-$40.45M
YoY Change	21.17%	-56.23%	121.29%
Depreciation, Depletion And Amortization	$800.0K	$800.0K	$400.0K
YoY Change	0.0%	100.0%	100.0%
Cash From Operating Activities	-$17.74M	-$36.08M	-$27.53M
YoY Change	-40.39%	31.06%	147.13%
INVESTING ACTIVITIES
Capital Expenditures	-$540.0K	-$210.0K	-$700.0K
YoY Change	-93.69%	-70.0%	1650.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$10.00K	-$4.060M
YoY Change	-100.0%	-100.25%
Cash From Investing Activities	-$540.0K	-$210.0K	-$4.760M
YoY Change	-88.0%	-95.59%	11800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.610M	1.460M	980.0K
YoY Change	-33.92%	48.98%	-99.27%
NET CHANGE
Cash From Operating Activities	-17.74M	-36.08M	-27.53M
Cash From Investing Activities	-540.0K	-210.0K	-4.760M
Cash From Financing Activities	2.610M	1.460M	980.0K
Net Change In Cash	-15.67M	-34.83M	-31.31M
YoY Change	-48.3%	11.24%	-125.55%
FREE CASH FLOW
Cash From Operating Activities	-$17.74M	-$36.08M	-$27.53M
Capital Expenditures	-$540.0K	-$210.0K	-$700.0K
Free Cash Flow	-$17.20M	-$35.87M	-$26.83M
YoY Change	-18.87%	33.69%	141.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38275081	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Prothena Corp plc
	dei	Trading Symbol TradingSymbol	PRTA
	prta	Accrued Offering Costs AccruedOfferingCosts	0	USD
	prta	Accrued Offering Costs AccruedOfferingCosts	31000	USD
CY2016Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	19073000	USD
CY2017Q2	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	20799000	USD
CY2017Q2	prta	Buildto Suit Leases At Cost BuildtoSuitLeasesAtCost	51800000	USD
	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	0	USD
	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	1002000	USD
CY2016Q4	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51359000	USD
CY2017Q2	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51760000	USD
CY2016Q4	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	51320000	USD
CY2017Q2	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	52100000	USD
CY2017Q2	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	52148000	USD
	prta	Capitalized Interestunder Buildto Suit Transaction CapitalizedInterestunderBuildtoSuitTransaction	326000	USD
	prta	Capitalized Interestunder Buildto Suit Transaction CapitalizedInterestunderBuildtoSuitTransaction	0	USD
CY2016Q2	prta	Collaboration Revenue CollaborationRevenue	333000	USD
	prta	Collaboration Revenue CollaborationRevenue	598000	USD
CY2017Q2	prta	Collaboration Revenue CollaborationRevenue	26812000	USD
	prta	Collaboration Revenue CollaborationRevenue	27071000	USD
CY2016Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2017Q2	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2016Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2017Q2	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2016Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2017Q2	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2016Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2017Q2	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2016Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2017Q2	prta	Deferred Shares Value DeferredSharesValue	0	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	325000	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	1830000	USD
	prta	Noncash Investingand Financing Items Stock Option Shortfall NoncashInvestingandFinancingItemsStockOptionShortfall	11000	USD
	prta	Noncash Investingand Financing Items Stock Option Shortfall NoncashInvestingandFinancingItemsStockOptionShortfall	0	USD
	prta	Noncashamountcapitalizedunderbuildtosuittransaction Noncashamountcapitalizedunderbuildtosuittransaction	37571000	USD
	prta	Noncashamountcapitalizedunderbuildtosuittransaction Noncashamountcapitalizedunderbuildtosuittransaction	0	USD
	prta	Numberof Votes NumberofVotes	1	vote
CY2017Q2	prta	Purchaseand Contractual Obligation Due After Fifth Year PurchaseandContractualObligationDueAfterFifthYear	860000	USD
CY2017Q2	prta	Purchaseand Contractual Obligation Due Next Fiscal Year PurchaseandContractualObligationDueNextFiscalYear	22676000	USD
CY2017Q2	prta	Purchaseand Contractual Obligation Duein Fifth Year PurchaseandContractualObligationDueinFifthYear	100000	USD
CY2017Q2	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	132000	USD
CY2017Q2	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	7106000	USD
CY2017Q2	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	15723000	USD
CY2017Q2	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	46597000	USD
CY2017Q2	prta	Sharebased Compensation Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationExcessTaxBenefitAmountBookedtoIncomeTaxProvision	1500000	USD
	prta	Sharebased Compensation Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationExcessTaxBenefitAmountBookedtoIncomeTaxProvision	3400000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13069000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	12545000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	178000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30240000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	378000	USD
CY2017Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	404000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	98000	USD
CY2017Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	0	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	435000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	351000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7668000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6231000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	654266000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	828792000	USD
CY2016Q4	us-gaap	Assets Assets	459976000	USD
CY2017Q2	us-gaap	Assets Assets	579000000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	391362000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	511720000	USD
CY2016Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	68614000	USD
CY2017Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	67280000	USD
CY2016Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	363000	USD
CY2017Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	714000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	386923000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	471729000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	370586000	USD
CY2016Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	447004000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	390979000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	475785000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	76418000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	84806000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34752116	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38156959	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34752116	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38156959	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	348000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	382000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-854000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	157000	USD
CY2016Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	363000	USD
CY2017Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	49000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2080000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	277000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	5913000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	5756000	USD
CY2016Q2	us-gaap	Depreciation Depreciation	400000	USD
	us-gaap	Depreciation Depreciation	700000	USD
CY2017Q2	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Depreciation Depreciation	1500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	679000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1518000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.99
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6629000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4234000	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	2096000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	5000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8134000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15316000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10912000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21744000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-40256000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-67596000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18988000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-56033000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	189000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	370000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1287000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2948000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	877000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	691000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9349000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4311000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-145000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30062000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2331000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8744000	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-10000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	267000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	18000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-346000	USD
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2769000	USD
CY2017Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	580000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	94573000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	92024000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	459976000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	579000000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41075000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	39599000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	53498000	USD
CY2017Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	52425000	USD
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9629000	USD
CY2017Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9020000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	129743000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	161334000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-942000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2607000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52383000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73921000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-40445000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-67966000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-17701000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53085000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	16000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	393000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-96000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-856000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1630000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	40493000	USD
	us-gaap	Operating Expenses OperatingExpenses	68168000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	44944000	USD
	us-gaap	Operating Expenses OperatingExpenses	81474000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-40160000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-67570000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18132000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54403000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1931000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	118000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	237000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	237000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	236000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	236000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	867000	USD
CY2016Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000	USD
CY2017Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	200000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2193000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1625000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8555000	USD
CY2017Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5851000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-86000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-293000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-874000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1284000	USD
CY2016Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1128000	USD
CY2017Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1217000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	942000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	2712000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4261000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9751000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	128777000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150323000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	105000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	966000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12013000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64120000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62074000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56452000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55843000	USD
CY2017Q2	us-gaap	Purchase Obligation PurchaseObligation	44872000	USD
CY2017Q2	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2017Q2	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2017Q2	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	32000	USD
CY2017Q2	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	22271000	USD
CY2017Q2	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	6976000	USD
CY2017Q2	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	15593000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32359000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52852000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34032000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59730000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-289211000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-342198000	USD
CY2016Q2	us-gaap	Revenues Revenues	333000	USD
	us-gaap	Revenues Revenues	598000	USD
CY2017Q2	us-gaap	Revenues Revenues	26812000	USD
	us-gaap	Revenues Revenues	27071000	USD
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	4546000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8270000	USD
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	6653000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12255000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	365403000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	486976000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34358000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34192000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38073000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36922000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment and Concentration of Risks</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivable from Roche as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> are amounts due from Roche entities located in the U.S. and Switzerland under the License Agreement that became effective January 22, 2014. Revenue recorded in the Statements of Operations consists of reimbursement from Roche for research and development services. Credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$55.1 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$55.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. </font></div><div style="line-height:120%;padding-top:15px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all pre-clinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation and research and development expenses. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001559053-17-000025-index-headers.html	Edgar Link	pending
0001559053-17-000025-index.html	Edgar Link	pending
0001559053-17-000025.txt	Edgar Link	pending
0001559053-17-000025-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
prothenabibioletteragimage50.jpg	Edgar Link	pending
prothenargbfullcolor.jpg	Edgar Link	pending
prta-20170630.xml	Edgar Link	completed
prta-20170630.xsd	Edgar Link	pending
prta-20170630_cal.xml	Edgar Link	unprocessable
prta-20170630_def.xml	Edgar Link	unprocessable
prta-20170630_lab.xml	Edgar Link	unprocessable
prta-20170630_pre.xml	Edgar Link	unprocessable
prta2017q210-q.htm	Edgar Link	pending
prta2017q210-qex102noonber.htm	Edgar Link	pending
prta2017q210-qex103zagopro.htm	Edgar Link	pending
prta2017q210-qex104lettera.htm	Edgar Link	pending
prta2017q210-qxex311.htm	Edgar Link	pending
prta2017q210-qxex312.htm	Edgar Link	pending
prta2017q210-qxex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2017 Q3 Form 10-Q Financial Statement

#000155905317000025 Filed on August 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2017 Q3 Form 10-Q Financial Statement

#000155905317000025 Filed on August 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta